Latest Pegloticase Stories
New review outlines the data supporting the relationship between urate-lowering efficacy and the risk for infusion reactions with Krystexxa® (pegloticase), the only FDA-approved treatment for chronic
Topical BioMedics—the formulators of Topricin—is helping doctors and patients have more options and better tools to create improved treatment protocols for gout and other ailments.
Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan.
- To give a box on the ear to.